Cargando…

P1379: OPTIMIZATION OF FLUDARABINE PHARMACOKINCETICS TO REDUCE THE RELAPSE INCIDENCE IN AML PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales:	Thavayogarajah, T., Nair, G., Balabanov, S., Manz, M. G., Müller, D., Schanz, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430518/ http://dx.doi.org/10.1097/01.HS9.0000848376.24818.fe

Ejemplares similares

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
por: Chevallier, Patrice, et al.
Publicado: (2016)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Editorial: The Elephant in the Room: AML Relapse After Allogeneic Hematopoietic Cell Transplantation
por: Battipaglia, Giorgia, et al.
Publicado: (2022)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2020)

Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease
por: Widmer, Corinne C., et al.
Publicado: (2017)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

P1282: MOCRAVIMOD IMPROVES OVERALL SURVIVAL IN AML PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Medinger, Michael, et al.
Publicado: (2023)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2018)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years
por: Hofer, Kevin D., et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation
por: Park, Woochan, et al.
Publicado: (2023)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Malagola, Michele, et al.
Publicado: (2014)

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
por: Finke, Jürgen, et al.
Publicado: (2022)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas
por: Delioukina, Maria, et al.
Publicado: (2011)

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E, et al.
Publicado: (2017)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

1379. Vaccination Rates among Liver Transplant Recipients at a Tertiary Care Hospital in Newark, NJ
por: Varughese, Tilly, et al.
Publicado: (2021)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E., et al.
Publicado: (2018)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia
por: Jamal, Saba, et al.
Publicado: (2021)

Role of Radiation Based Conditioning Regimens in Patients With High-Risk AML Undergoing Allogenic Transplantation in Remission or Active Disease and Mechanisms of Post-Transplant Relapse
por: Salhotra, Amandeep, et al.
Publicado: (2022)

Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report
por: Annaloro, Claudio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_omkaf2qe1o8c4bh4h94irvie9q